rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Aziz Sawaf

SVP & Chief Financial Officer

Company insider

Files Form 4 as: SVP & Chief Financial Officer, Theravance Biopharma.

In numbers

Trades disclosed
29
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
0
First trade
20 Feb 2023
Last trade
23 Sep 2026
Last filed
24 Sep 2026

Companies traded

Where they are an officer
Theravance BiopharmaOfficer · Pharmaceuticals · last 23 Sep 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—204,966filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—108,436filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—23,439filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—204,966filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—108,436filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—23,439filing
20 Aug 2026filed 24 Aug 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$137K8,112 at $16.95filing
20 Aug 2026filed 24 Aug 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$137K8,112 at $16.95filing
20 May 2026filed 22 May 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$143K8,670 at $16.55filing
20 May 2026filed 22 May 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$143K8,670 at $16.55filing
1 Apr 2026filed 3 Apr 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code A—37,500 at $0.00filing
1 Apr 2026filed 3 Apr 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code A—37,500 at $0.00filing
20 Feb 2026filed 24 Feb 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$406K20,672 at $19.66filing
20 Feb 2026filed 24 Feb 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$406K20,672 at $19.66filing
20 Nov 2025filed 24 Nov 2025Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$333K18,627 at $17.90filing
20 Aug 2025filed 22 Aug 2025Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$125K9,368 at $13.39filing
20 May 2025filed 22 May 2025Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$88K9,348 at $9.45filing
28 Feb 2025filed 4 Mar 2025Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code A—75,000 at $0.00filing
20 Feb 2025filed 24 Feb 2025Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$133K13,751 at $9.66filing
20 Nov 2024filed 22 Nov 2024Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code F$85K8,477 at $9.97filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Weiss Asset Management LPOther role · Other at Theravance Biopharma, filing Form 4 there in the last year
Deepika PakianathanDirector · Director at Theravance Biopharma, filing Form 4 there in the last year
Rick E. WinninghamChief Executive Officer · Chief Executive Officer at Theravance Biopharma, filing Form 4 there in the last year
Aine MillerSVP, Dev & Head of Ire Office · SVP, Dev & Head of Ire Office at Theravance Biopharma, filing Form 4 there in the last year
Brett A. GrimaudSVP, Gen Counsel and Secretary · SVP, Gen Counsel and Secretary at Theravance Biopharma, filing Form 4 there in the last year